The controversial place of vitamin C in cancer treatment

Biochemical Pharmacology

Volumn 76, Issue 12, 2008, Pages 1644-1652

  Verrax, J ^a   Buc Calderon, P ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Ascorbic acid; Cancer; Vitamin C

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; ASPARAGINASE; BLEOMYCIN; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; HYDROGEN PEROXIDE; LIPID HYDROPEROXIDE; METHOTREXATE; PACLITAXEL; PROCARBAZINE; SEMIQUINONE; TRANSITION ELEMENT; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER THERAPY; CARDIOVASCULAR DISEASE; CYTOTOXICITY; DIETARY INTAKE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG INDICATION; DRUG METABOLISM; DRUG STRUCTURE; FENTON REACTION; HUMAN; HYDROXYLATION; IRON ABSORPTION; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REDUCTION;

EID: 56749160108     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.024     Document Type: Note

References (109)

1. Szent-Györgyi A. Observations on the function of peroxidase systems and the chemistry of the adrenal cortex: description of a new carbohydrate derivative. Biochem J 22 (1928) 1387-1409
2. Svirbely J., and Szent-Györgyi A. The chemical nature of vitamin C. Biochem J 26 (1932) 865-870
3. Svirbely J., and Szent-Györgyi A. The chemical nature of vitamin C. Biochem J 27 (1933) 279-285
4. Bánhegyi G., Braun L., Csala M., Puskás F., and Mandl J. Ascorbate metabolism and its regulation in animals. Free Radic Biol Med 23 (1997) 793-803
5. Levine M., Conry-Cantilena C., Wang Y., Welch R., Washko P., Dhariwal K., et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93 (1996) 3704-3709
6. Levine M., Wang Y., Padayatty S., and Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 98 (2001) 9842-9846
7. Korcok J., Dixon S., Lo T., and Wilson J. Differential effects of glucose on dehydroascorbic acid transport and intracellular ascorbate accumulation in astrocytes and skeletal myocytes. Brain Res 993 (2003) 201-207
8. Agus D., Gambhir S., Pardridge W., Spielholz C., Baselga J., Vera J., et al. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest 100 (1997) 2842-2848
9. Vera J., Rivas C., Fischbarg J., and Golde D. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 364 (1993) 79-82
10. Takanaga H., Mackenzie B., and Hediger M. Sodium-dependent ascorbic acid transporter family SLC23. Pflugers Arch 447 (2004) 677-682
11. Montel-Hagen A., Kinet S., Manel N., Mongellaz C., Prohaska R., Battini J., et al. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell 132 (2008) 1039-1048
12. Winkler B., Orselli S., and Rex T. The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective. Free Radic Biol Med 17 (1994) 333-349
13. Park J., and Levine M. Purification, cloning and expression of dehydroascorbic acid-reducing activity from human neutrophils: identification as glutaredoxin. Biochem J 315 Pt 3 (1996) 931-938
14. May J., Mendiratta S., Hill K., and Burk R. Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J Biol Chem 272 (1997) 22607-22610
15. Carr A., and Frei B. Does vitamin C act as a pro-oxidant under physiological conditions?. FASEB J 13 (1999) 1007-1024
16. Buettner G. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 300 (1993) 535-543
17. May J., Cobb C., Mendiratta S., Hill K., and Burk R. Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase. J Biol Chem 273 (1998) 23039-23045
18. Buettner G., and Jurkiewicz B. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 145 (1996) 532-541
19. González M., Miranda-Massari J., Mora E., Guzmán A., Riordan N., Riordan H., et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther 4 (2005) 32-44
20. Drouin R., Rodriguez H., Gao S., Gebreyes Z., O'Connor T., Holmquist G., et al. Cupric ion/ascorbate/hydrogen peroxide-induced DNA damage: DNA-bound copper ion primarily induces base modifications. Free Radic Biol Med 21 (1996) 261-273
21. Clément M., Ramalingam J., Long L., and Halliwell B. The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid Redox Signal 3 (2001) 157-163
22. O'Connell M., Ward R., Baum H., and Peters T. The role of iron in ferritin- and haemosiderin-mediated lipid peroxidation in liposomes. Biochem J 229 (1985) 135-139
23. Pethig R., Gascoyne P., McLaughlin J., and Szent-Györgyi A. Ascorbate-quinone interactions: electrochemical, free radical, and cytotoxic properties. Proc Natl Acad Sci USA 80 (1983) 129-132
24. Verrax J., Delvaux M., Beghein N., Taper H., Gallez B., and Buc Calderon P. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells: an in vitro comparative study. Free Radic Res 39 (2005) 649-657
25. Padayatty S., Katz A., Wang Y., Eck P., Kwon O., Lee J., et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 22 (2003) 18-35
26. Davidsson L. Approaches to improve iron bioavailability from complementary foods. J Nutr 133 (2003) 1560S-1562S
27. Douglas R., Hemilä H., Chalker E., and Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev (2007) [CD000980]
28. Bjelakovic G., Nikolova D., Gluud L., Simonetti R., and Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev (2008) [CD007176]
29. De Laurenzi V., Melino G., Savini I., Annicchiarico-Petruzzelli M., Finazzi-Agrò A., and Avigliano L. Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. Eur J Cancer 31A (1995) 463-466
30. Prasad K., Sinha P., Ramanujam M., and Sakamoto A. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA 76 (1979) 829-832
31. Noto V., Taper H., Jiang Y., Janssens J., Bonte J., and De Loecker W. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. Cancer 63 (1989) 901-906
32. Casciari J., Riordan N., Schmidt T., Meng X., Jackson J., and Riordan H. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer 84 (2001) 1544-1550
33. Chen Q., Espey M., Krishna M., Mitchell J., Corpe C., Buettner G., et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102 (2005) 13604-13609
34. Song J., Shin S., and Ross G. Oxidative stress induced by ascorbate causes neuronal damage in an in vitro system. Brain Res 895 (2001) 66-72
35. Halliwell B. Vitamin C and genomic stability. Mutat Res 475 (2001) 29-35
36. 2 and transition metal ions in the genotoxic action of ascorbic acid in cell culture models. Toxicol Lett 170 (2007) 57-65
37. Chen Q., Espey M., Sun A., Lee J., Krishna M., Shacter E., et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104 (2007) 8749-8754
38. Chen Q., Espey M., Sun A., Pooput C., Kirk K., Krishna M., et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105 (2008) 11105-11109
39. Podmore I., Griffiths H., Herbert K., Mistry N., Mistry P., and Lunec J. Vitamin C exhibits pro-oxidant properties. Nature 392 (1998) 559
40. Childs A., Jacobs C., Kaminski T., Halliwell B., and Leeuwenburgh C. Supplementation with vitamin C and N-acetyl-cysteine increases oxidative stress in humans after an acute muscle injury induced by eccentric exercise. Free Radic Biol Med 31 (2001) 745-753
41. 2-induced damage and iron homeostasis in human cells. Free Radic Biol Med 43 (2007) 1165-1175
42. Park C., Amare M., Savin M., and Hoogstraten B. Growth suppression of human leukemic cells in vitro by l-ascorbic acid. Cancer Res 40 (1980) 1062-1065
43. Zhang W., Negoro T., Satoh K., Jiang Y., Hashimoto K., Kikuchi H., et al. Synergistic cytotoxic action of vitamin C and vitamin K3. Anticancer Res 21 (2001) 3439-3444
44. Gatenby R., and Gillies R. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 4 (2004) 891-899
45. Langemann H., Torhorst J., Kabiersch A., Krenger W., and Honegger C. Quantitative determination of water- and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int J Cancer 43 (1989) 1169-1173
46. Agus D., Vera J., and Golde D. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 59 (1999) 4555-4558
47. Vera J., Rivas C., Zhang R., Farber C., and Golde D. Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid. Blood 84 (1994) 1628-1634
48. Vafa O., Wade M., Kern S., Beeche M., Pandita T., Hampton G., et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9 (2002) 1031-1044
49. Sattler M., Verma S., Shrikhande G., Byrne C., Pride Y., Winkler T., et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275 (2000) 24273-24278
50. Raffaghello L., Lee C., Safdie F., Wei M., Madia F., Bianchi G., et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci USA 105 (2008) 8215-8220
51. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10 (2006) 241-252
52. Trachootham D., Zhang H., Zhang W., Feng L., Du M., Zhou Y., et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood (2008)
53. Laurent A., Nicco C., Chéreau C., Goulvestre C., Alexandre J., Alves A., et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65 (2005) 948-956
54. Verrax J., Cadrobbi J., Marques C., Taper H., Habraken Y., Piette J., et al. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis 9 (2004) 223-233
55. Sun Y., Oberley L., Elwell J., and Sierra-Rivera E. Antioxidant enzyme activities in normal and transformed mouse liver cells. Int J Cancer 44 (1989) 1028-1033
56. Yang J., Lam E., Hammad H., Oberley T., and Oberley L. Antioxidant enzyme levels in oral squamous cell carcinoma and normal human oral epithelium. J Oral Pathol Med 31 (2002) 71-77
57. Oberley T., and Oberley L. Antioxidant enzyme levels in cancer. Histol Histopathol 12 (1997) 525-535
58. Baker A., Oberley L., and Cohen M. Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 32 (1997) 229-233
59. Coursin D., Cihla H., Sempf J., Oberley T., and Oberley L. An immunohistochemical analysis of antioxidant and glutathione S-transferase enzyme levels in normal and neoplastic human lung. Histol Histopathol 11 (1996) 851-860
60. Sun Y., Colburn N., and Oberley L. Depression of catalase gene expression after immortalization and transformation of mouse liver cells. Carcinogenesis 14 (1993) 1505-1510
61. Sun Y., Oberley L., Oberley T., Elwell J., and Sierra-Rivera E. Lowered antioxidant enzymes in spontaneously transformed embryonic mouse liver cells in culture. Carcinogenesis 14 (1993) 1457-1463
62. Kinnula V., and Crapo J. Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med 36 (2004) 718-744
63. Breen A., and Murphy J. Reactions of oxyl radicals with DNA. Free Radic Biol Med 18 (1995) 1033-1077
64. Alexandre J., Batteux F., Nicco C., Chéreau C., Laurent A., Guillevin L., et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119 (2006) 41-48
65. Ramanathan B., Jan K., Chen C., Hour T., Yu H., and Pu Y. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65 (2005) 8455-8460
66. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J 401 (2007) 1-11
67. Chiang C., Song E., Yang V., and Chao C. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem J 301 Pt 3 (1994) 759-764
68. Song E., Yang V., Chiang C., and Chao C. Potentiation of growth inhibition due to vincristine by ascorbic acid in a resistant human non-small cell lung cancer cell line. Eur J Pharmacol 292 (1995) 119-125
69. Grad J., Bahlis N., Reis I., Oshiro M., Dalton W., and Boise L. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98 (2001) 805-813
70. Kurbacher C., Wagner U., Kolster B., Andreotti P., Krebs D., and Bruckner H. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103 (1996) 183-189
71. Dai J., Weinberg R., Waxman S., and Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93 (1999) 268-277
72. Taper H., de Gerlache J., Lans M., and Roberfroid M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer 40 (1987) 575-579
73. Kassouf W., Highshaw R., Nelkin G., Dinney C., Kamat A., and Vitamins C. K3 sensitize human urothelial tumors to gemcitabine. J Urol 176 (2006) 1642-1647
74. Reddy V., Khanna N., Singh N., and Vitamin. C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53. Biochem Biophys Res Commun 282 (2001) 409-415
75. Bahlis N., McCafferty-Grad J., Jordan-McMurry I., Neil J., Reis I., Kharfan-Dabaja M., et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8 (2002) 3658-3668
76. Taper H., Keyeux A., and Roberfroid M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res 16 (1996) 499-503
77. Zou W., Yue P., Lin N., He M., Zhou Z., Lonial S., et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12 (2006) 273-280
78. Perez-Cruz I., Cárcamo J., and Golde D. Caspase-8 dependent TRAIL-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 12 (2007) 225-234
79. Karasavvas N., Cárcamo J., Stratis G., and Golde D. Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 105 (2005) 4004-4012
80. Pathak A., Bhutani M., Guleria R., Bal S., Mohan A., Mohanti B., et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr 24 (2005) 16-21
81. Brown J., and Wilson W. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
82. Rankin E., and Giaccia A. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15 (2008) 678-685
83. Fong G., and Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ 15 (2008) 635-641
84. Semenza G. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
85. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S., et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 65 (2005) 7249-7258
86. Pagé E., Chan D., Giaccia A., Levine M., and Richard D. Hypoxia-inducible factor-1{alpha} stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 19 (2008) 86-94
87. Vissers M., Gunningham S., Morrison M., Dachs G., and Currie M. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med 42 (2007) 765-772
88. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12 (2007) 230-238
89. Dewhirst M., Cao Y., and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8 (2008) 425-437
90. McCormick W. Cancer: a collagen disease, secondary to a nutritional deficiency. Arch Pediatr 76 (1959) 166-171
91. Bodansky O., Wroblewski F., and Markardt B. Concentrations of ascorbic acid in plasma and white blood cells of patients with cancer and noncancerous chronic disease. Cancer 5 (1952) 678-684
92. Mayland C., Bennett M., and Allan K. Vitamin C deficiency in cancer patients. Palliat Med 19 (2005) 17-20
93. Georgiannos S., Weston P., and Goode A. Micronutrients in gastrointestinal cancer. Br J Cancer 68 (1993) 1195-1198
94. Cameron E., Pauling L., and Leibovitz B. Ascorbic acid and cancer: a review. Cancer Res 39 (1979) 663-681
95. Cameron E., and Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73 (1976) 3685-3689
96. Cameron E., and Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 75 (1978) 4538-4542
97. Comroe J.J. Experimental studies designed to evaluate the management of patients with incurable cancer. Proc Natl Acad Sci USA 75 (1978) 4543
98. DiPalma J., and McMichael R. The interaction of vitamins with cancer chemotherapy. CA Cancer J Clin 29 (1979) 280-286
99. Creagan E., Moertel C., O'Fallon J., Schutt A., O'Connell M., Rubin J., et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Engl J Med 301 (1979) 687-690
100. Moertel C., Fleming T., Creagan E., Rubin J., O'Connell M., and Ames M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Engl J Med 312 (1985) 137-141
101. Drisko J., Chapman J., and Hunter V. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 22 (2003) 118-123
102. Ries L., Melbert D., Krapcho M., Stinchcomb D., Howlader N., Horner M., et al. SEER cancer statistics review, 1975-2005 (2008), National Cancer Institute, Bethesda
103. Padayatty S., Riordan H., Hewitt S., Katz A., Hoffer L., and Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 174 (2006) 937-942
104. Hoffer L., Levine M., Assouline S., Melnychuk D., Paddayatty S., Rosadiuk K., et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol (2008)
105. Verrax J., Vanbever S., Stockis J., Taper H., and Calderon P. Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells. Int J Cancer 120 (2007) 1192-1197
106. Rees D., Kelsey H., and Richards J. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306 (1993) 841-842
107. Peña de la Vega L., Lieske J., Milliner D., Gonyea J., and Kelly D. Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. JPEN J Parenter Enteral Nutr 28 (2004) 435-438
108. Massey L., Liebman M., and Kynast-Gales S. Ascorbate increases human oxaluria and kidney stone risk. J Nutr 135 (2005) 1673-1677
109. Vickers A., Kuo J., and Cassileth B. Unconventional anticancer agents: a systematic review of clinical trials. J Clin Oncol 24 (2006) 136-140